An Open-Label, Multicenter, Phase 1 Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Intravenous Doses of Inhibrx rhAAT-Fc (INBRX-101) in Adults with Alpha-1 Antitrypsin Deficiency (AATD)
-
- STATUS
- Recruiting
Summary
The purpose of the study is to assess safety and tolerability of a Phase I drug, INBRX-101 in patients with alpha-1 antitrypsin deficiency (AATD).
Description
Here at IU Health, we are recruiting for clinical trial to study the effects of a new drug on Alpha-1 Antitrypsin Deficiency (AATD). All study procedures will take place at University Hospital at no cost to you. You will be compensated for your time and effort.
Details
| Condition | Alpha-1 Antitrypsin Deficiency (AATD) |
|---|---|
| Age | 18years - 70years |
| Clinical Study Identifier | TX10435 |
| Last Modified on | 19 February 2024 |
Eligibility
How to participate?
,
Send a message
Enter your contact details to connect with study team
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.